866-997-4948(US-Canada Toll Free)

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 67 Pages

NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Review, H2 2016, provides in depth analysis on NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
- The report reviews NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NT-3 Growth Factor Receptor (TrkC Tyrosine Kinase or Tyrosine Kinase Receptor C or GP145-TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) Overview 7
Therapeutics Development 8
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Products under Development by Stage of Development 8
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Products under Development by Therapy Area 9
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Products under Development by Indication 10
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Products under Development by Companies 14
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 24
Array BioPharma Inc 24
AstraZeneca Plc 25
Daiichi Sankyo Company Ltd 26
Ignyta Inc 27
Loxo Oncology, Inc. 28
Netris Pharma SAS 29
PharmatrophiX Inc 30
SOM Biotech SL 31
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Drug Profiles 32
AR-523 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AZD-7451 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DS-6051 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
entrectinib - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
lestaurtinib - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LM-22B10 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
LOXO-101 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Agonize TrkC for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Monoclonal Antibody to Inhibit TrkC for Oncology - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
PLX-7486 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Dormant Projects 50
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Discontinued Products 51
NT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) - Featured News & Press Releases 52
Dec 12, 2016: Loxo Oncology to Present Updated LOXO-101 Adult Phase 1 Data at the European Society for Medical Oncology Asia Congress 52
Dec 02, 2016: Late-Breaking Oral Plenary Presentation of a Novel Entrectinib Combination Regimen at the 2016 EORTC-NCI-AACR Annual Meeting 52
Nov 29, 2016: Ignyta to Present Pre-clinical Data on Entrectinib at the 2016 EORTC-NCI-AACR Annual Meeting 53
Nov 15, 2016: Ignyta Announces EAP Designation and CE Marking for its Trailblaze Pharos Clinical Trial Assay 53
Sep 19, 2016: EORTC and Ignyta Expand Collaborative Agreement for Precision Medicine 54
Aug 31, 2016: Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial 55
Jul 13, 2016: Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 55
Jun 15, 2016: Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee 56
Apr 19, 2016: Loxo Oncology Announces First Pediatric Response to LOXO-101 56
Apr 17, 2016: Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in AACR Phase 1 Update 58
Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting 60
Apr 11, 2016: Loxo Oncology to Present Updated LOXO-101 Phase 1 Data at the 2016 AACR Annual Meeting 62
Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting 63
Jan 15, 2016: Loxo Oncology Announces EMA Orphan Drug Designation Granted to LOXO-101 for Treatment of Soft Tissue Sarcoma 64
Dec 22, 2015: Loxo Oncology Announces First Patient Enrolled in Phase 1 Trial of LOXO-101 in Pediatric Cancer Patients 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Products under Development by Companies, H2 2016 (Contd..2) 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Array BioPharma Inc, H2 2016 24
Pipeline by AstraZeneca Plc, H2 2016 25
Pipeline by Daiichi Sankyo Company Ltd, H2 2016 26
Pipeline by Ignyta Inc, H2 2016 27
Pipeline by Loxo Oncology, Inc., H2 2016 28
Pipeline by Netris Pharma SAS, H2 2016 29
Pipeline by PharmatrophiX Inc, H2 2016 30
Pipeline by SOM Biotech SL, H2 2016 31
Dormant Projects, H2 2016 50
Discontinued Products, H2 2016 51

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *